Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
27.73
+0.31 (1.13%)
At close: Dec 5, 2025, 4:00 PM EST
28.00
+0.27 (0.97%)
After-hours: Dec 5, 2025, 7:59 PM EST
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $12.88M in the quarter ending September 30, 2025, with 43.69% growth. This brings the company's revenue in the last twelve months to $44.79M, up 36.26% year-over-year. In the year 2024, Agios Pharmaceuticals had annual revenue of $36.50M with 36.07% growth.
Revenue (ttm)
$44.79M
Revenue Growth
+36.26%
P/S Ratio
35.70
Revenue / Employee
$91,785
Employees
488
Market Cap
1.62B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AGIO News
- 17 days ago - Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript - Seeking Alpha
- 17 days ago - Why Shares in Agios Pharmaceuticals Got Crushed Today - The Motley Fool
- 17 days ago - Why Is Agios Pharmaceuticals Stock Sinking Today? - Benzinga
- 17 days ago - Agios Pharma reports mixed results in late-stage study for sickle cell disease drug - Reuters
- 17 days ago - Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease - GlobeNewsWire
- 4 weeks ago - Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones - Seeking Alpha
- 4 weeks ago - Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition - GlobeNewsWire
- 5 weeks ago - Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript - Seeking Alpha